News Releases
All Releases
View Summary Peregrine to Report Third Quarter Fiscal Year 2012 Financial Results After Market on March 9, 2012
Mar 1, 2012
PDF 14.8 KB Add to Briefcase
View Summary Peregrine Announces Seven Abstracts Accepted for Presentation at AACR 2012 Annual Meeting
Mar 1, 2012
PDF 22.6 KB Add to Briefcase
View Summary Peregrine Announces Participation at Upcoming Investor Conferences in March
Feb 27, 2012
PDF 14.8 KB Add to Briefcase
View Summary Avid Bioservices to Present at IBC's Antibody Development and Production Conference
Feb 23, 2012
PDF 16.6 KB Add to Briefcase
View Summary Peregrine to Present at BIO CEO and Investor Conference on Tuesday, February 14, 2012 at 8:30 AM EST
Feb 9, 2012
PDF 14.2 KB Add to Briefcase
View Summary Peregrine Provides Update on HCV Clinical Program
Dec 29, 2011
PDF 19.3 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Second Quarter 2012 Financial Results and Recent Developments
Dec 12, 2011
PDF 29.2 KB Add to Briefcase
View Summary Peregrine's Bavituximab Shows 50% Improvement in Overall Tumor Response Rate in Randomized Phase II Lung Cancer Trial
Dec 6, 2011
PDF 18.9 KB Add to Briefcase
View Summary Peregrine to Report Second Quarter Fiscal Year 2012 Financial Results After Market on December 12, 2011
Dec 5, 2011
PDF 14.8 KB Add to Briefcase
View Summary Peregrine Reports Promising 23.2 Month Median Overall Survival From Phase II Advanced Breast Cancer Trial
Nov 22, 2011
PDF 19.6 KB Add to Briefcase
View Summary Peregrine to Present at Lazard Healthcare Conference November 15, 2011 at 11:30 AM EST
Nov 8, 2011
PDF 15.3 KB Add to Briefcase
View Summary Peregrine Completes Patient Enrollment in Second-Line Non-Small Cell Lung Cancer Trial; Data to Be Unblinded in First Half 2012
Oct 6, 2011
PDF 18.8 KB Add to Briefcase
View Summary Peregrine Completes Patient Enrollment in Randomized Phase II HCV Trial for Bavituximab
Sep 26, 2011
PDF 18.6 KB Add to Briefcase
View Summary Peregrine to Present at JMP Securities Healthcare Conference September 27, 2011 at 12:00 PM EDT
Sep 20, 2011
PDF 13.7 KB Add to Briefcase
View Summary Peregrine PS-Targeting Antibodies Show Broad Potential to Image Tumors and Assess Cancer Therapy Response
Sep 12, 2011
PDF 19.5 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2012 Financial Results and Recent Developments
Sep 9, 2011
PDF 27.9 KB Add to Briefcase
View Summary Peregrine Completes Patient Enrollment in Randomized Phase II Trial for Bavituximab in Front-Line Non-Small Cell Lung Cancer
Sep 8, 2011
PDF 19.9 KB Add to Briefcase
View Summary Peregrine to Report First Quarter Fiscal Year 2012 Financial Results Before Market on September 9, 2011
Sep 2, 2011
PDF 13.8 KB Add to Briefcase
View Summary Peregrine Prices $7 Million Registered Direct Offering of Common Stock
Sep 2, 2011
PDF 14.6 KB Add to Briefcase
View Summary Peregrine to Present at Stifel Nicolaus Healthcare Conference September 8, 2011 at 11:30 AM EDT
Sep 1, 2011
PDF 13.7 KB Add to Briefcase
Showing 61-80 of 517 Page: 1 2 3 4 5 6 7 8 ... 26 Previous 20 | Next 20
Add to Briefcase = add release to Briefcase
Print E-mail